NOVO-B.CO vs. LLY.DE
Compare and contrast key facts about Novo Nordisk A/S (NOVO-B.CO) and Eli Lilly and Company (LLY.DE).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NOVO-B.CO or LLY.DE.
Correlation
The correlation between NOVO-B.CO and LLY.DE is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NOVO-B.CO vs. LLY.DE - Performance Comparison
Key characteristics
NOVO-B.CO:
-0.64
LLY.DE:
0.64
NOVO-B.CO:
-0.69
LLY.DE:
1.09
NOVO-B.CO:
0.91
LLY.DE:
1.14
NOVO-B.CO:
-0.56
LLY.DE:
1.01
NOVO-B.CO:
-1.20
LLY.DE:
2.49
NOVO-B.CO:
21.43%
LLY.DE:
8.76%
NOVO-B.CO:
40.20%
LLY.DE:
34.17%
NOVO-B.CO:
-64.64%
LLY.DE:
-79.63%
NOVO-B.CO:
-38.48%
LLY.DE:
-2.06%
Fundamentals
NOVO-B.CO:
DKK 2.61T
LLY.DE:
€755.55B
NOVO-B.CO:
DKK 22.65
LLY.DE:
€11.20
NOVO-B.CO:
26.38
LLY.DE:
74.97
NOVO-B.CO:
1.19
LLY.DE:
0.87
NOVO-B.CO:
DKK 290.40B
LLY.DE:
€31.51B
NOVO-B.CO:
DKK 245.88B
LLY.DE:
€25.50B
NOVO-B.CO:
DKK 108.58B
LLY.DE:
€10.22B
Returns By Period
In the year-to-date period, NOVO-B.CO achieves a 0.93% return, which is significantly lower than LLY.DE's 15.06% return. Over the past 10 years, NOVO-B.CO has underperformed LLY.DE with an annualized return of 17.62%, while LLY.DE has yielded a comparatively higher 32.58% annualized return.
NOVO-B.CO
0.93%
8.32%
-30.92%
-25.34%
25.91%
17.62%
LLY.DE
15.06%
17.26%
1.13%
20.16%
46.89%
32.58%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NOVO-B.CO vs. LLY.DE — Risk-Adjusted Performance Rank
NOVO-B.CO
LLY.DE
NOVO-B.CO vs. LLY.DE - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NOVO-B.CO) and Eli Lilly and Company (LLY.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NOVO-B.CO vs. LLY.DE - Dividend Comparison
NOVO-B.CO's dividend yield for the trailing twelve months is around 1.57%, more than LLY.DE's 0.56% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NOVO-B.CO Novo Nordisk A/S | 1.57% | 1.59% | 1.01% | 2.09% | 1.27% | 2.02% | 2.11% | 2.64% | 2.27% | 3.69% | 1.25% | 1.73% |
LLY.DE Eli Lilly and Company | 0.56% | 0.62% | 0.75% | 1.03% | 1.12% | 1.83% | 1.89% | 1.87% | 2.39% | 2.34% | 0.00% | 0.00% |
Drawdowns
NOVO-B.CO vs. LLY.DE - Drawdown Comparison
The maximum NOVO-B.CO drawdown since its inception was -64.64%, smaller than the maximum LLY.DE drawdown of -79.63%. Use the drawdown chart below to compare losses from any high point for NOVO-B.CO and LLY.DE. For additional features, visit the drawdowns tool.
Volatility
NOVO-B.CO vs. LLY.DE - Volatility Comparison
Novo Nordisk A/S (NOVO-B.CO) has a higher volatility of 12.91% compared to Eli Lilly and Company (LLY.DE) at 8.36%. This indicates that NOVO-B.CO's price experiences larger fluctuations and is considered to be riskier than LLY.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NOVO-B.CO vs. LLY.DE - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities